Amryt Pharma Holdings Ltd banner

Amryt Pharma Holdings Ltd
LSE:AMYT

Watchlist Manager
Amryt Pharma Holdings Ltd Logo
Amryt Pharma Holdings Ltd
LSE:AMYT
Watchlist
Price: 143 GBX -11.73%
Market Cap: £457.1m

Relative Value

AMYT price has not been updated for more than 1 year. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of AMYT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMYT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

AMYT Competitors Multiples
Amryt Pharma Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
453.2m GBP 0 -0.1 0 -0
US
Eli Lilly and Co
NYSE:LLY
986.9B USD 15.1 47.8 32.2 34.4
US
Johnson & Johnson
NYSE:JNJ
596.5B USD 6.3 22.3 15.4 19
CH
Roche Holding AG
SIX:ROG
283.9B CHF 4.7 30.5 12.9 15
CH
Novartis AG
SIX:NOVN
247.6B CHF 5.7 23 14.2 18.2
UK
AstraZeneca PLC
LSE:AZN
238.1B GBP 5.5 31.5 17.4 24.5
US
Merck & Co Inc
NYSE:MRK
305.9B USD 4.7 16.8 10.4 12.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.4 10.3 7.6 8.9
US
Pfizer Inc
NYSE:PFE
156.9B USD 2.5 20.2 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 17.8 7.4 9.2
P/E Multiple
Earnings Growth PEG
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average P/E: 24.5
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.3
7%
3.2
CH
Roche Holding AG
SIX:ROG
30.5
29%
1.1
CH
Novartis AG
SIX:NOVN
23
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
31.5
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.8
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
7%
1.5
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.8
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average EV/EBITDA: 42.7
0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
15.4
2%
7.7
CH
Roche Holding AG
SIX:ROG
12.9
5%
2.6
CH
Novartis AG
SIX:NOVN
14.2
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
17.4
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.4
3%
3.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
2%
3.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Amryt Pharma Holdings Ltd
LSE:AMYT
Average EV/EBIT: 101.7
Negative Multiple: -0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
22%
1.6
US
Johnson & Johnson
NYSE:JNJ
19
7%
2.7
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
CH
Novartis AG
SIX:NOVN
18.2
9%
2
UK
AstraZeneca PLC
LSE:AZN
24.5
21%
1.2
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
3%
3
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.2
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett